Optimizing the dose in patients treated with imatinib as first line treatment for gastrointestinal stromal tumours: A cost‐effectiveness study

por Zuidema, Sander, Desar, Ingrid M.E., van Erp, Nielka P., Kievit, Wietske
Publicado 2019

Deep and ongoing response of castrate-resistant prostate cancer on very low-dose enzalutamide in an elderly chemotherapy–naïve patient: a case report

por Boerrigter, Emmy, Havenith, Thomas, van Erp, Nielka P., Schnog, John-John B.
Publicado 2021

The impact of patient characteristics on enzalutamide pharmacokinetics and how this relates to treatment toxicity and efficacy in metastatic prostate cancer patients

por Benoist, Guillemette E., van Oort, Inge M., Burger, David M., Mehra, Niven, van Erp, Nielka P.
Publicado 2020

Clinical Pharmacokinetics and Pharmacodynamics of the Next Generation Androgen Receptor Inhibitor—Darolutamide

por Podgoršek, Eva, Mehra, Niven, van Oort, Inge M., Somford, Diederik M., Boerrigter, Emmy, van Erp, Nielka P.
Publicado 2023

Imatinib, sunitinib and pazopanib: From flat‐fixed dosing towards a pharmacokinetically guided personalized dose

por Westerdijk, Kim, Desar, Ingrid M.E., Steeghs, Neeltje, van der Graaf, Winette T.A., van Erp, Nielka P.
Publicado 2020

Quantification of cobimetinib, cabozantinib, dabrafenib, niraparib, olaparib, vemurafenib, regorafenib and its metabolite regorafenib M2 in human plasma by UPLC–MS/MS

por Krens, Stefanie D., van der Meulen, Eric, Jansman, Frank G.A., Burger, David M., van Erp, Nielka P.
Publicado 2020

Systemic exposure to cisplatin and paclitaxel after intraperitoneal chemotherapy in ovarian cancer

por de Jong, Loek A. W., Lambert, Marie, van Erp, Nielka P., de Vries, Lukas, Chatelut, Etienne, Ottevanger, Petronella B.
Publicado 2023

Effect of gastrointestinal resection on sunitinib exposure in patients with GIST

por de Wit, Djoeke, van Erp, Nielka P, Khosravan, Reza, Wiltshire, Robin, Allred, Randy, Demetri, George D, Guchelaar, Henk-Jan, Gelderblom, Hans
Publicado 2014

The effect of gastrectomy on regorafenib exposure and progression‐free survival in patients with advanced gastrointestinal stromal tumours

por Lubberman, Floor J.E., van der Graaf, Winette T.A., Xu, Lei, Cleton, Adriaan, Demetri, George D., Gelderblom, Hans, van Erp, Nielka P.
Publicado 2019

A prospective phase I multicentre randomized cross-over pharmacokinetic study to determine the effect of food on abiraterone pharmacokinetics

por Lubberman, Floor J. E., Benoist, Guillemette E., Gerritsen, Winald, Burger, David M., Mehra, Niven, Hamberg, Paul, van Oort, Inge, van Erp, Nielka P.
Publicado 2019

The effect of chemotherapy on the exposure–response relation of abiraterone in metastatic castration‐resistant prostate cancer

por Boerrigter, Emmy, Benoist, Guillemette E., Overbeek, Joanneke K., Donders, Rogier, Mehra, Niven, van Oort, Inge M., ter Heine, Rob, van Erp, Nielka P.
Publicado 2021

Measuring Tumour Imatinib Concentrations in Gastrointestinal Stromal Tumours: Relevant or Redundant?

por Giraud, Eline L., de Jong, Loek A. W., van den Hombergh, Erik, Kaal, Suzanne E. J., van Erp, Nielka P., Desar, Ingrid M. E.
Publicado 2023

A Semi-Physiological Population Model to Quantify the Effect of Hematocrit on Everolimus Pharmacokinetics and Pharmacodynamics in Cancer Patients

por van Erp, Nielka P., van Herpen, Carla M., de Wit, Djoeke, Willemsen, Annelieke, Burger, David M., Huitema, Alwin D. R., Kapiteijn, Ellen, ter Heine, Rob
Publicado 2016

The relationship between sunitinib exposure and both efficacy and toxicity in real‐world patients with renal cell carcinoma and gastrointestinal stromal tumour

por Westerdijk, Kim, Krens, Stefanie D., van der Graaf, Winette T.A., Mulder, Sasja F., van Herpen, Carla M.L., Smilde, Tineke, van Erp, Nielka P., Desar, Ingrid M.E.
Publicado 2020

Marginal increase of sunitinib exposure by grapefruit juice

por van Erp, Nielka P., Baker, Sharyn D., Zandvliet, Anthe S., Ploeger, Bart A., den Hollander, Margaret, Chen, Zhaoyuan, den Hartigh, Jan, König-Quartel, Jacqueline M. C., Guchelaar, Henk-Jan, Gelderblom, Hans
Publicado 2010

Pharmacokinetic Aspects of the Two Novel Oral Drugs Used for Metastatic Castration-Resistant Prostate Cancer: Abiraterone Acetate and Enzalutamide

por Benoist, Guillemette E., Hendriks, Rianne J., Mulders, Peter F. A., Gerritsen, Winald R., Somford, Diederik M., Schalken, Jack A., van Oort, Inge M., Burger, David M., van Erp, Nielka P.
Publicado 2016

Exposure‐toxicity relationship of cabozantinib in patients with renal cell cancer and salivary gland cancer

por Krens, Stefanie D., van Boxtel, Wim, Uijen, Maike J. M., Jansman, Frank G. A., Desar, Ingrid M. E., Mulder, Sasja F., van Herpen, Carla M. L., van Erp, Nielka P.
Publicado 2021

Model-Informed Precision Dosing of Everolimus: External Validation in Adult Renal Transplant Recipients

por Zwart, Tom C., Moes, Dirk Jan A. R., van der Boog, Paul J. M., van Erp, Nielka P., de Fijter, Johan W., Guchelaar, Henk-Jan, Keizer, Ron J., ter Heine, Rob
Publicado 2020

The Impact of Dose and Simultaneous Use of Acid-Reducing Agents on the Effectiveness of Vemurafenib in Metastatic BRAF V600 Mutated Melanoma: a Retrospective Cohort Study

por Knapen, Lotte M., Koornstra, Rutger H. T., Driessen, Johanna H. M., van Vlijmen, Bas, Croes, Sander, Schalkwijk, Stein, Colbers, Angela, Gerritsen, Winald R., Burger, David M., de Vries, Frank, van Erp, Nielka P.
Publicado 2018

Exposure–response analyses of cabozantinib in patients with metastatic renal cell cancer

por Krens, Stefanie D., van Erp, Nielka P., Groenland, Stefanie L., Moes, Dirk Jan A. R., Mulder, Sasja F., Desar, Ingrid M. E., van der Hulle, Tom, Steeghs, Neeltje, van Herpen, Carla M. L.
Publicado 2022